Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Elanco US Inc. is currently managing 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 10 pending office actions are distributed among 10 distinct examiners, which indicates the level of examiner diversity for the portfolio. Furthermore, the prosecution involves 9 distinct art units, suggesting that the 10 pending office actions cover a variety of specialized technical fields within Biotechnology & Pharmaceuticals. This distribution across 9 distinct art units requires a broad technical approach.
RAHMANI, NILOOFAR is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. This 1 busiest examiner pending action is one of the 10 pending office actions that the company must address. With 10 distinct examiners and 9 distinct art units, the applicant must manage a prosecution landscape where filings are spread across various officials. The 10 pending office actions will require strategies tailored to the specific standards of the 9 distinct art units. Practitioners should focus on the individual tendencies of RAHMANI, NILOOFAR for the 1 busiest examiner pending action while preparing for feedback across the other 10 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §102 only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| BARBER, KIMBERLY | 1 | 73.6% | +18.5% |
| MARTINEZ, TARA L | 1 | 62.6% | +65.4% |
| JOHNSON, DANIELLE D | 1 | 45.0% | +12.9% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| MENSH, ANDREW J | 1 | 64.3% | +19.2% |
| PHAN, DOAN THI-THUC | 1 | 42.7% | +47.7% |
| CURRENS, GRANT CARSON | 1 | 54.6% | +62.5% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | — |
| 18207959 | SHROUD DEVICE | MENSH, ANDREW J | — |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | — |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17524709 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | PHAN, DOAN THI-THUC | 4d overdue |
| 18576593 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | BARBER, KIMBERLY | — |
| 18566294 | METHODS OF INHIBITING BOVINE MASTITIS DURING THE DRY PERIOD | MARTINEZ, TARA L | — |
| 18212953 | ANTIMICROBIAL CLAY COMPOSITIONS AND METHODS OF USING | JOHNSON, DANIELLE D | — |
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | — |
| 18207959 | SHROUD DEVICE | MENSH, ANDREW J | — |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | — |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1615 | 1 |
| 1617 | 1 |
| 1642 | 1 |
| 3781 | 1 |
| 1613 | 1 |
| 1651 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694487 | STABLE FORMULATIONS OF BUPRENORPHINE | RAHMANI, NILOOFAR | 1691 | §102 | Final Rejection | — | Pending | Mar 22, 2024 |
| 18576593 | PROCESS FOR MAKING DIARYL ISOXAZOLINE DERIVATIVE | BARBER, KIMBERLY | 1615 | §112DP | Final Rejection | — | Pending | Jan 04, 2024 |
| 18566294 | METHODS OF INHIBITING BOVINE MASTITIS DURING THE DRY PERIOD | MARTINEZ, TARA L | — | §103DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18212953 | ANTIMICROBIAL CLAY COMPOSITIONS AND METHODS OF USING | JOHNSON, DANIELLE D | 1617 | §103Other | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258071 | TNF ALPHA AND NGF ANTIBODIES FOR VETERINARY USE | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18207959 | SHROUD DEVICE | MENSH, ANDREW J | 3781 | §102§103 | Final Rejection | — | Pending | Jun 09, 2023 |
| 17524709 | CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE | PHAN, DOAN THI-THUC | 1613 | §103§112DP | Final Rejection | 4d overdue | Pending | Nov 11, 2021 |
| 17432725 | MICROBIAL TREATMENT | CURRENS, GRANT CARSON | 1651 | §102§103 | Final Rejection | — | Pending | Aug 20, 2021 |
| 17284875 | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use | NGUYEN, NAM P | 1678 | §103§112 | Final Rejection | — | Pending | Apr 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial